SCHEMBL1468754

SCHEMBL1468754

O=[N+]([O-])c1c[nH]c2ncc(F)c(F)c12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 1/20 0.35
CASP6 P55212 2/20 0.33
RAB9A P51151 2/20 0.33
PIM3 Q86V86 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
ATM Q13315 1/20 0.33
ALDH1A1 P00352 3/20 0.32
HIF1A Q16665 1/20 0.32
DYRK1A Q13627 1/20 0.31
DYRK1B Q9Y463 1/20 0.31
HTT P42858 1/20 0.31
MAPT P10636 3/20 0.30
KDM4E B2RXH2 2/20 0.30
VCAM1 P19320 1/20 0.30
PIN1 Q13526 1/20 0.30
MEN1 O00255 2/20 0.30
KMT2A Q03164 2/20 0.30
LMNA P02545 1/20 0.30
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15155185 0.84 KDM4E (0.35) METRAB9ASMN1; SMN2TDP1ALDH1A1
SCHEMBL1467726 0.84 ALDH1A1 (0.33) METRAB9ASMN1; SMN2TDP1ALDH1A1
SCHEMBL1468836 0.84 MAPT (0.35) METRAB9ASMN1; SMN2ALDH1A1MAPT
SCHEMBL15155089 0.81 ALDH1A1 (0.37) SMN1; SMN2TDP1ALDH1A1HTTMAPT
SCHEMBL1471061 0.79 ALDH1A1 (0.36) RAB9ASMN1; SMN2ALDH1A1MAPTMEN1
SCHEMBL3723388 0.77 MET (0.43) METCASP6RAB9APIM3TDP1
SCHEMBL31403638 0.76 KDM4E (0.36) METCASP6RAB9APIM3SMN1; SMN2
SCHEMBL1469302 0.76 LMNA (0.37) RAB9ASMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL16533894 0.74 MAPT (0.36) METRAB9ASMN1; SMN2ALDH1A1DYRK1A
SCHEMBL15154894 0.74 MAPT (0.39) ALDH1A1HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9969727-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2018-05-15 US disclosed
US-20160368916-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-12-22 US disclosed
US-9365568-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2016-06-14 US disclosed
EP-2990407-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS Array Biopharma, Inc. (US) 2016-03-02 EP disclosed
US-20150322061-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2015-11-12 US disclosed
CN-104926810-A Pyrrolopyridines As Kinase Inhibitors ARRAY BIOPHARMA INC 2015-09-23 CN disclosed
EP-2307409-B1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2015-08-12 EP disclosed
CN-102089307-B Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC 2015-07-01 CN disclosed
US-8981085-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2015-03-17 US disclosed
US-20140243520-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-08-28 US disclosed
US-8758830-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA, INC. (US) 2014-06-24 US disclosed
US-20140100369-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-04-10 US disclosed
US-8545897-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2013-10-01 US disclosed
US-20130045286-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2013-02-21 US disclosed
US-8178131-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2012-05-15 US disclosed
EP-2307409-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS Array Biopharma, Inc. (US) 2011-04-13 EP disclosed
US-20110070317-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-03-24 US disclosed
WO-2009140320-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243520-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A MET 3405/4885CASP6 2581/4885RAB9A 2866/4885
US-20160368916-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A MET 3405/4885CASP6 2581/4885RAB9A 2866/4885
US-20140100369-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A MET 3405/4885CASP6 2581/4885RAB9A 2866/4885
US-20110070317-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, BUB1B MET 2892/4885CASP6 2264/4885RAB9A 2639/4885
US-20150322061-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A MET 3405/4885CASP6 2581/4885RAB9A 2866/4885
US-20130045286-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A MET 3405/4885CASP6 2581/4885RAB9A 2866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.